Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors — Stella

Recruiting

Back to Melanoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of Arizona

Collaborators

Amgen

Enrollment target

~30 participants

Started

September 2025

Primary completion

May 2030

Age range

18 Years – 99 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov